Morgan Stanley’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.36K | Sell |
1,671
-8,917
| -84% | -$10.4K | ﹤0.01% | 7375 |
|
|
2026
Q1 | $14.2K | Buy |
10,588
+9,124
| +623% | +$15K | ﹤0.01% | 6845 |
|
|
2025
Q4 | $2.34K | Sell |
1,464
-177
| -11% | -$365 | ﹤0.01% | 7215 |
|
|
2025
Q3 | $4.2K | Buy |
1,641
+61
| +4% | +$192 | ﹤0.01% | 7136 |
|
|
2025
Q2 | $2.86K | Sell |
1,580
-186
| -11% | -$308 | ﹤0.01% | 7155 |
|
|
2025
Q1 | $3.58K | Buy |
1,766
+154
| +10% | +$575 | ﹤0.01% | 7071 |
|
|
2024
Q4 | $9.64K | Sell |
1,612
-926
| -36% | -$7.74K | ﹤0.01% | 6817 |
|
|
2024
Q3 | $24.8K | Sell |
2,538
-4,747
| -65% | -$63.8K | ﹤0.01% | 6441 |
|
|
2024
Q2 | $149K | Sell |
7,285
-6,609
| -48% | -$221K | ﹤0.01% | 5799 |
|
|
2024
Q1 | $627K | Buy |
13,894
+1,909
| +16% | +$91.1K | ﹤0.01% | 5208 |
|
|
2023
Q4 | $566K | Sell |
11,985
-720
| -6% | -$40K | ﹤0.01% | 5239 |
|
|
2023
Q3 | $514K | Buy |
12,705
+6,901
| +119% | +$698K | ﹤0.01% | 5158 |
|
|
2023
Q2 | $618K | Sell |
5,804
-2,327
| -29% | -$775K | ﹤0.01% | 5110 |
|
|
2023
Q1 | $2.43M | Buy |
8,131
+319
| +4% | +$136K | ﹤0.01% | 4335 |
|
|
2022
Q4 | $2.68M | Sell |
7,812
-8,109
| -51% | -$1.96M | ﹤0.01% | 4266 |
|
|
2022
Q3 | $3.01M | Buy |
15,921
+1,743
| +12% | +$405K | ﹤0.01% | 4111 |
|
|
2022
Q2 | $2.99M | Buy |
14,178
+989
| +7% | +$208K | ﹤0.01% | 4213 |
|
|
2022
Q1 | $4.41M | Sell |
13,189
-1,481
| -10% | -$429K | ﹤0.01% | 3817 |
|
|
2021
Q4 | $4.77M | Buy |
14,670
+7,124
| +94% | +$3.06M | ﹤0.01% | 3770 |
|
|
2021
Q3 | $3.66M | Buy |
7,546
+92
| +1% | +$40.5K | ﹤0.01% | 4046 |
|
|
2021
Q2 | $3.47M | Buy |
7,454
+5,937
| +391% | +$3.24M | ﹤0.01% | 4156 |
|
|
2021
Q1 | $1.05M | Buy |
1,517
+114
| +8% | +$91.7K | ﹤0.01% | 4705 |
|
|
2020
Q4 | $1.04M | Buy |
1,403
+283
| +25% | +$220K | ﹤0.01% | 4649 |
|
|
2020
Q3 | $777K | Buy |
1,120
+663
| +145% | +$498K | ﹤0.01% | 4383 |
|
|
2020
Q2 | $388K | Buy |
457
+178
| +64% | +$116K | ﹤0.01% | 4726 |
|
|
2020
Q1 | $100K | Sell |
279
-359
| -56% | -$129K | ﹤0.01% | 5185 |
|
|
2019
Q4 | $149K | Buy |
638
+468
| +275% | +$47K | ﹤0.01% | 5519 |
|
|
2019
Q3 | $19K | Buy |
170
+167
| +5,567% | +$26.3K | ﹤0.01% | 6027 |
|
|
2019
Q2 | $0 | Sell |
3
-151
| -98% | -$25.6K | ﹤0.01% | 6647 |
|
|
2019
Q1 | $24K | Sell |
154
-105
| -41% | -$12.9K | ﹤0.01% | 5951 |
|
|
2018
Q4 | $16K | Sell |
259
-67
| -21% | -$5.65K | ﹤0.01% | 6057 |
|
|
2018
Q3 | $41K | Buy |
326
+249
| +323% | +$37K | ﹤0.01% | 5925 |
|
|
2018
Q2 | $11K | Sell |
77
-106
| -58% | -$16.2K | ﹤0.01% | 6278 |
|
|
2018
Q1 | $30K | Buy |
+183
| New | +$30.6K | ﹤0.01% | 6024 |
|
Other funds holding BTAI
OCM
OFA
Morgan Stanley's BTAI Position: Q2 2026 in Review
Morgan Stanley reduced its BioXcel Therapeutics (BTAI) stake by 84% in Q2 2026, selling an estimated $10.4K and leaving 1,671 shares worth $2.36K. The position accounts for ﹤0.01% of the portfolio, ranked #7375.
Morgan Stanley first reported a position in BTAI in Q1 2018 and has held it in 34 quarters since. The position peaked at $4.77M in Q4 2021. 47 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.
- Morgan Stanley held 1,671 shares of BioXcel Therapeutics worth $2.36K as of Q2 2026.
- Morgan Stanley sold 8,917 BioXcel Therapeutics shares in Q2 2026, an estimated $10.4K.
- BioXcel Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7375 holding.
- Morgan Stanley first reported a position in BioXcel Therapeutics in Q1 2018 and has held it in 34 quarters since.
- Morgan Stanley's BioXcel Therapeutics position peaked at $4.77M in Q4 2021.
- 47 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.